INTRODUCTION
Skin and soft tissue infections (SSTIs) are a common reason for patients seeking inpatient and outpatient medical care with more than 14 million outpatient visits a year [1] , and almost 900 000 inpatient admissions in the United States [2] . Pathogen isolation in SSTIs is limited by currently available diagnostics and is influenced by host and geographic factors, making empiric antimicrobial therapy selection complicated [3 && ,4,5] . Despite difficulties in empiric therapy selection, it is well recognized that patients with severe SSTIs require source control via surgical debridement. In this review, we summarize the salient features of the treatment of severe SSTIs.
DEFINING SEVERITY IN SOFT TISSUE INFECTIONS
Severity of illness due to SSTI loosely correlates with depth of skin structure involvement, though there is no universally agreed upon severity scoring system. For the purposes of this review, we will consider patients with toxic shock syndrome (TSS), necrotizing fasciitis, or gas gangrene/myonecrosis as having a severe SSTI. In addition, patients having any SSTI meeting criteria for severe sepsis or septic shock or having a quick Sequential Organ Failure Assessment score at least 2 will be considered to have a severe SSTI. Table 1 lists some of the common pathogens in severe SSTI, their features, and recommended antimicrobials.
TYPES OF SEVERE SOFT TISSUE INFECTIONS
organisms) are important to inform empiric antimicrobial decisions [4, 6] . Patients with severe forms of purulent SSTIs, cellulitis, or surgical site infection should receive broad-spectrum antibiotic therapy [including a Methicillin-resistant Staphylococcus aureus (MRSA) agent when high risk] and source control, when applicable.
Toxic shock syndrome
TSS is a fulminant infection typically due to Staphylococcus aureus or Streptococcus pyogenes, though similar syndromes can occur with groups B, C, and G streptococci, and Clostridium species. The annual incidence of staphylococcal TSS (SaTSS) is 0.5/ 100 000 and 0.4/100 000 for streptococcal TSS (SeTSS), though local rates may vary [7] . Mortality rates are less than 5% for menstrual SaTSS, 5-22% for nonmenstrual SaTSS, and 30-70% for SeTSS [7] . Clostridial toxic shock is rare and its incidence is uncertain [8, 9] .
When TSS is suspected, empiric therapy must cover for drug-resistant infections. Expert opinion based on retrospective studies and in-vitro data highlight vancomycin and clindamycin or linezolid alone as possible treatment regimens [10] [11] [12] [13] . Nafcillin or oxacillin are good choices for methicillinsensitive SaTSS, but must be used in combination with clindamycin as nafcillin alone can increase toxin production [12] . Clindamycin or linezolid are essential in treatment as they reduce superantigen production in both SaTSS and SeTSS [11] [12] [13] . When susceptibilities are available, antibiotics should be de-escalated while still including an agent that suppresses toxin production until clinical stability is achieved. For clostridial TSS, clindamycin and penicillin should be used, though there is limited data on this syndrome to guide treatment.
Intravenous immunoglobulin (IVIG) nonspecifically binds and inactivates superantigens, limiting cytokine storm in TSS, though the clinical benefits are controversial. Recruitment for randomized controlled trials (RCTs) of IVIG has been difficult due to the rarity of TSS [14] . One study found significantly improved mortality in patients that received IVIG or clindamycin for SeTSS [15] . IVIG is less studied in SaTSS, though in one study five confirmed cases received IVIG and none expired [16] .
In a cohort of patients with mixed bacterial causes of necrotizing SSTI, IVIG showed no benefit in mortality or functional outcomes [17 && ], though only roughly one-thirds had S. pyogenes or S. aureus.
KEY POINTS
Severe skin and SSTIs initially require intensive care, source control, and broad-spectrum antimicrobials.
Intravenous immunoglobulin use in toxic shock syndrome remains controversial, but can be considered for severe cases.
For necrotizing skin and SSTIs, surgical consultation is paramount.
Imaging studies cannot rule out necrotizing infection and should not delay surgical interventions.
Pathogen-directed therapy and antimicrobial deescalation should be the goal of severe skin and SSTI treatment when clinical stability is achieved. ]. Given the ongoing mixed evidence, IVIG can be considered in patients with TSS, but benefit is unclear and specific dosing regimens are not well studied (Fig. 1 ).
Necrotizing soft tissue infections: gas gangrene/myonecrosis and necrotizing fasciitis
Necrotizing SSTIs are difficult to treat and require aggressive surgical debridement, broad-spectrum antimicrobials, and intensive care. Table 2 and Fig. 1 demonstrate factors associated with increased likelihood of necrotizing infection and a proposed management tree [19] . Source control of infection is paramount and serial surgical debridements are generally required. The frequency and number of required debridements varies, but generally debridement should occur every 24-48 h until there is no evidence of necrosis. Daily wound dressing changes should be done to look for ongoing infection (e.g., bullae, devitalized tissue, spreading erythema) that would require repeat debridement. Increased requirements for intensive care support or laboratory parameters suggestive of worsening infection (e.g., progressive renal failure, increasing leukocytosis, increasing lactate) should prompt discussion of repeat debridement. Surgical control of infection is particularly important because diffusion of antimicrobials into affected tissues is limited due to significant tissue edema, necrosis, inflammation, and penetrating vessel thromboses [20] .
Gas gangrene/myonecrosis
Gas gangrene or myonecrosis is caused by Clostridium species and should be managed surgically with adjunctive broad-spectrum antibiotics while awaiting culture results (Table 1) . Though rare, Clostridium sordellii infections are notable as they can be associated with a toxic-shock like syndrome, particularly in patients with recent parturition or abortion [8, 9, 21] . TSS from clostridial infection is pathophysiologically dissimilar to SeTSS or SaTSS, making IVIG of dubitable benefit [8, 9, 21] .
Necrotizing fasciitis
Necrotizing fasciitis (Fig. 2) is a rare SSTI that involves the deep fascia [19] . Rates of necrotizing fasciitis vary widely based on region (0.18-15.5 per 100 000) and are increasing over time [22, 23] . Despite patients with necrotizing fasciitis having a higher severity of illness than patients with cellulitis, a recent study found that patients with cellulitis and necrotizing fasciitis had similar in-hospital and 90-day mortality, presumably due to higher comorbidity burden in patients with cellulitis [24 & ]. However, the study had a small number of patients and may not have been powered to detect a difference in mortality between the groups.
Type I necrotizing fasciitis is polymicrobial, including aerobic and anaerobic organisms. Type II necrotizing fasciitis is classically caused by S. pyogenes, though S. aureus also falls into this category. There are a variety of less frequently encountered agents causing necrotizing fasciitis, which makes it important for practitioners to realize the importance of surgical debridement with attendant bacterial cultures in combination with broad-spectrum antimicrobials as the first lines of therapy [25, 26] .
Though the classic teaching for necrotizing fasciitis is pain out proportion to physical examination findings, it is important to remember that superficial nerves can undergo necrosis, resulting in anesthesia of affected areas. A high degree of suspicion for necrotizing SSTI is required due to variability in physical examination findings and low sensitivity of imaging modalities. Imaging findings cannot rule out necrotizing fasciitis and may delay surgical intervention, which is associated with poor outcomes [27] . However, in clinically stable patients, MRI may be helpful in distinguishing necrotizing from nonnecrotizing infection [28] .
Necrotizing fasciitis predominates on the lower extremity and predisposing conditions such as diabetes and peripheral vascular disease reflect this localization. Due to the relative rarity and heterogeneity of microbiologic causes, no clinical trials are available to guide duration of therapy. Based on expert opinion, recent guidelines suggest antimicrobial therapy directed against cultured organisms for at least 48-72 h after patients are clinically stable and require no further operative interventions [4] .
Surgical considerations
For all patients with severe SSTIs, general resuscitative measures should be followed in accordance with institutional protocols. Source control is paramount, which may include surgical debridement, removal of invasive devices, or vaginal examination in the case of menstrual TSS. Prolonged time from presentation to first surgical intervention is associated with increased mortality [27, 29] . In a mixed cohort of severe sepsis/septic shock patients that included patients with SSTIs, source control was associated with reduced mortality despite patients requiring source control having greater severity of illness [30 && ]. In conjunction with serial debridements, vacuum-assisted closure of wounds may contribute to healing [31] . For cases of necrotizing infection involving the perineum or other sites with potential for stool contamination, temporary colostomy may be required to assist in wound healing. Rates of amputation in lower extremity necrotizing fasciitis vary from 15 to 72% based on comorbidities, with diabetes being a strong risk factor for amputation [32] . Although potentially life-saving, it is important to recognize that amputations, among other factors, may be associated with significant functional limitations after discharge [33] .
Hyperbaric oxygen therapy
The use of hyperbaric oxygen therapy (HBOT) for necrotizing SSTI remains controversial due to mixed evidence of benefit, a lack of RCTs, and variable access to hyperbaric oxygen chambers [34] [35] [36] [37] [38] . In the absence of RCTs or well done propensity score FIGURE 2. Necrotizing fasciitis of the lower extremity. Retiform purpura with bullae formation (a) or rapidly spreading erythema with bullae formation (b) should prompt urgent surgical consultation. Adapted from [19] .
analyses, we cannot recommend for or against the use of adjunctive HBOT for the management of necrotizing SSTI. For centers with HBOT readily available, its use can be considered, but should not be a substitute for or result in delays in surgical or antimicrobial therapy (Fig. 1) .
Antimicrobial considerations
As a general rule, all severe SSTI should be treated empirically with broad-spectrum antibiotics directed against typical pathogens, specifically MRSA, resistant Gram-negatives, and anaerobes (Table 1 and Table 3 
Considerations for selected antimicrobials
Dalbavancin and oritavancin are long-acting semisynthetic lipoglycopeptides that are approved for a wide range of Gram-positive organisms. However, further studies are needed before their use can be recommended for severe SSTI. Daptomycin use may be contraindicated in patients with necrotizing fasciitis and elevated creatine kinase levels. As MRSA is one of the most common causes of SSTIs and severe illness is associated with higher rates of bacteremia, caution is advised when using linezolid, as its use in MRSA bacteremia may be associated with worse outcomes in patients with acute physiology and chronic health evaluation II scores at least 14 [43] . Tedizolid has been shown to be noninferior to linezolid across a range of SSTI severity [44 & ], but there is no reason to believe it would be more efficacious in MRSA bacteremia than linezolid, so concerns about its empiric use remain. Telavancin is associated with higher rates of toxicity than other available agents for SSTI, and we therefore do not recommend its use when other agents can be employed. Though approved for SSTIs, tigecycline has been linked with worse outcomes in patients with severe illness. Tigecycline may also be a risk factor for treatment failure in patients with drug-resistant infections. As such, we recommend avoiding tigecycline therapy when other options are available.
Future therapies
There are some exciting new drugs in the pipeline for SSTI treatment, including delafloxacin and omadacycline, but discussion of their use will be covered by other articles in this issue. Nontraditional therapies for SSTIs, such as an antistaphylococcal alpha toxin antibody, have recently shown some promise in animal models, but are not available for human use [45 & ].
SPECIAL CONSIDERATIONS
Unusual causes of SSTI are outside the scope of this review, as most are rare and not typically associated with severe illness. For additional information, see recent reviews on this subject [19] . 
Immunocompromised hosts
Immunodeficiency changes the physical examination findings of SSTI, the putative pathogens, and the diagnostic and treatment plans. The differential diagnosis for dermatologic findings in the immunocompromised host includes noninfectious causes and a broader range of infections, including invasive fungal, mycobacterial, and parasitic infections [4, 19] . With a broader differential diagnosis and greater potential for decompensation, early dermatologic consultation for immunocompromised patients may be beneficial [ 
CONCLUSION
SSTIs have a variety of presentations and can be severe enough to require intensive care. Practitioners should be familiar with the spectrum of clinical presentations for SSTI that require urgent surgical debridement to avoid delays in surgery as this can lead to worsened outcomes. Aggressive source control and broad spectrum antimicrobials are essential for all severe SSTI, with empiric therapy guided by knowledge of patient risk factors, the local antibiogram, and where available, rapid diagnostic testing.
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